43038 Long term psoriasis control with guselkumab versus secukinumab and ixekizumab among bio- naïve patients: analysis of drug persistence in large claims database

BACKGROUND: In the clinical trial setting, guselkumab was more effective than secukinumab at one year. Long-term treatment persistence, a valuable measure of drug performance in real-world setting, was compared among bio-naïve patient with psoriasis initiated on guselkumab versus common interleukin-17 agents.